. Author manuscript; available in PMC: 2020 Mar 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2018 Nov 28;28(3):563–569. doi: 10.1158/1055-9965.EPI-18-0965

Table 2.

Associations between current aspirin and NA-NSAID use and prostate cancer incidence and mortality among 6,594 men in the ARIC study, 1987–2012

	Prostate Cancer Incidence					Prostate Cancer Mortality
		Age-Adjusted		Multivariable-Adjusted^a			Age-Adjusted		Multivariable-Adjusted^a
	Events/Person-years	HR	(95% CI)	HR	(95% CI)	Events/Person-years	HR	(95% CI)	HR	(95% CI)

Aspirin Use
No	503 / 75897	1	(Ref)	1	(Ref)	65 / 84565	1	(Ref)	1	(Ref)
Yes	314 / 43478	0.96	(0.84–1.11)	1.05	(0.91–1.22)	25 / 48951	0.52	(0.33–0.82)	0.59	(0.36–0.96)
NA-NSAID Use
No	633 / 96626	1	(Ref)	1	(Ref)	71 / 107724	1	(Ref)	1	(Ref)
Yes	184 / 22749	1.15	(0.98–1.36)	1.16	(0.98–1.37)	19 / 25792	1.02	(0.62–1.70)	1.02	(0.62–1.71)

Abbreviations: NA-NSAID, non-aspirin nonsteroidal anti-inflammatory drug; ARIC, Atherosclerosis Risk in Communities; HR, hazard ratio; CI, confidence interval

Adjusted for age, race/center, birth cohort, smoking status, BMI, current statin use, diabetes, prevalent CHD, education, family history of prostate cancer